X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2106) 2106
Publication (287) 287
Book Review (25) 25
Book / eBook (19) 19
Book Chapter (6) 6
Conference Proceeding (3) 3
Dissertation (2) 2
Magazine Article (2) 2
Data Set (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1583) 1583
index medicus (1417) 1417
animals (1070) 1070
male (724) 724
female (692) 692
intercellular signaling peptides and proteins - metabolism (637) 637
mice (471) 471
middle aged (375) 375
intercellular signaling peptides and proteins - genetics (361) 361
adult (327) 327
expression (290) 290
inflammation (280) 280
cell biology (258) 258
aged (256) 256
rats (256) 256
growth factors (242) 242
oncology (234) 234
research (226) 226
proteins (219) 219
intercellular signaling peptides and proteins - blood (214) 214
analysis (212) 212
gene expression (200) 200
signal transduction (199) 199
cancer (198) 198
health aspects (196) 196
article (194) 194
intercellular signaling peptides and proteins (194) 194
intercellular signaling peptides and proteins - therapeutic use (192) 192
disease models, animal (182) 182
cytokines (177) 177
stem cells (173) 173
cells, cultured (172) 172
angiogenesis (163) 163
care and treatment (162) 162
intercellular signaling peptides and proteins - pharmacology (162) 162
medicine (161) 161
physiological aspects (160) 160
research article (160) 160
apoptosis (156) 156
immunology (149) 149
biochemistry & molecular biology (148) 148
in-vitro (146) 146
endocrinology & metabolism (144) 144
medicine, research & experimental (144) 144
surgery (144) 144
intercellular signaling peptides and proteins - physiology (140) 140
mice, inbred c57bl (139) 139
gene-expression (138) 138
pharmacology & pharmacy (138) 138
risk factors (135) 135
multidisciplinary sciences (134) 134
medicine & public health (130) 130
rodents (130) 130
cells (128) 128
physiology (127) 127
cytokines - metabolism (124) 124
activation (123) 123
in-vivo (115) 115
intercellular signaling peptides and proteins - administration & dosage (114) 114
rats, sprague-dawley (113) 113
treatment outcome (110) 110
regeneration (107) 107
science (106) 106
immunohistochemistry (105) 105
hematology (103) 103
time factors (103) 103
vascular endothelial growth factor (102) 102
biomarkers - blood (101) 101
obesity (101) 101
cell proliferation (99) 99
cardiac & cardiovascular systems (98) 98
genetic aspects (98) 98
studies (98) 98
transplantation (97) 97
cell line, tumor (95) 95
neurosciences (95) 95
pathology (95) 95
vascular endothelial growth factor a (95) 95
vascular endothelial growth factors (94) 94
aged, 80 and over (92) 92
biology (91) 91
biotechnology & applied microbiology (91) 91
cell line (91) 91
growth (91) 91
intercellular-adhesion molecule-1 (90) 90
oxidative stress (90) 90
prognosis (90) 90
abridged index medicus (89) 89
tissue engineering (89) 89
disease (88) 88
endothelial growth-factor (87) 87
platelet-rich plasma (86) 86
mesenchymal stem-cells (85) 85
receptor (85) 85
dentistry (84) 84
proliferation (84) 84
insulin resistance (83) 83
adiponectin (81) 81
diabetes (81) 81
therapy (80) 80
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2098) 2098
Japanese (18) 18
Chinese (6) 6
French (6) 6
German (5) 5
Spanish (3) 3
Russian (2) 2
Danish (1) 1
Hungarian (1) 1
Italian (1) 1
Portuguese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2018, Volume 20, Issue 1, pp. 157 - 164
Aims Apelin is a recently identified adipokine known to improve glucose tolerance and insulin sensitivity in murine models. This study was dedicated to the... 
apelin/APJ system | type 2 diabetes | adipokine | hyperinsulinaemic‐euglycaemic clamp | insulin resistance | hyperinsulinaemic-euglycaemic clamp | apelin | APJ system | HEART-FAILURE | ENDOCRINOLOGY & METABOLISM | RESISTANT MICE | AGONIST | Apelin - analogs & derivatives | Overweight - drug therapy | Humans | Anti-Obesity Agents - adverse effects | Male | Apelin Receptors - agonists | Anti-Obesity Agents - therapeutic use | Apelin - blood | Dose-Response Relationship, Drug | Young Adult | Overweight - metabolism | Intercellular Signaling Peptides and Proteins - pharmacokinetics | Hypoglycemic Agents - administration & dosage | Adult | Intercellular Signaling Peptides and Proteins - administration & dosage | Body Mass Index | Hypoglycemic Agents - therapeutic use | Anti-Obesity Agents - administration & dosage | Double-Blind Method | Apelin - adverse effects | Peptide Fragments - administration & dosage | Insulin Resistance | Peptide Fragments - pharmacokinetics | Apelin - therapeutic use | Proof of Concept Study | Cross-Over Studies | Apelin Receptors - metabolism | Overweight - blood | Adolescent | Intercellular Signaling Peptides and Proteins - therapeutic use | Peptide Fragments - adverse effects | Peptide Fragments - therapeutic use | Glucose Clamp Technique | Infusions, Intravenous | Hypoglycemic Agents - adverse effects | Intercellular Signaling Peptides and Proteins - adverse effects | Type 2 diabetes | Obesity | Diabetics | Analysis | Insulin resistance | Glucose | Insulin | Dextrose | Glucose tolerance | Animal models | Intravenous administration | Diabetes mellitus | Rodents | Body weight
Journal Article
Circulation, ISSN 0009-7322, 03/2003, Volume 107, Issue 10, pp. 1359 - 1365
Journal Article
Journal of Allergy and Clinical Immunology, The, ISSN 0091-6749, 2015, Volume 136, Issue 2, pp. 441 - 453
Background Traffic-related particulate matter (PM) has been linked to a heightened incidence of asthma and allergic diseases. However, the molecular mechanisms... 
Allergy and Immunology | airway hyperresponsiveness | Traffic-related particulate matter | diesel exhaust particles | ultrafine particles | Jagged 1 | Notch | asthma | allergic airway inflammation | aryl hydrocarbon receptor | AMBIENT PARTICULATE MATTER | OXIDATIVE STRESS | DENDRITIC CELLS | IMMUNOLOGY | POLLUTION | NRF2 | ALLERGY | CHEMICALS | airway hyper-responsiveness | HEALTH | TRANSCRIPTION FACTOR | Allergens - adverse effects | Bronchial Hyperreactivity - immunology | Dendritic Cells - immunology | Humans | Dendritic Cells - pathology | Gene Expression Profiling | Monocytes - immunology | Bronchial Hyperreactivity - genetics | CD11c Antigen - immunology | Respiratory Hypersensitivity - pathology | CD11c Antigen - genetics | Immunoglobulin E - genetics | Calcium-Binding Proteins - immunology | Serrate-Jagged Proteins | T-Lymphocytes, Helper-Inducer - immunology | Monocytes - pathology | Vehicle Emissions | T-Lymphocytes, Helper-Inducer - pathology | Disease Models, Animal | Jagged-1 Protein | Bronchial Hyperreactivity - chemically induced | Signal Transduction | Membrane Proteins - genetics | Particulate Matter - adverse effects | Respiratory Hypersensitivity - chemically induced | Gene Expression Regulation | Intercellular Signaling Peptides and Proteins - genetics | Receptors, Aryl Hydrocarbon - genetics | Receptor, Notch1 - immunology | Membrane Proteins - immunology | Mice, Transgenic | Respiratory Hypersensitivity - immunology | Receptors, Cell Surface - immunology | Respiratory Hypersensitivity - genetics | Bronchial Hyperreactivity - pathology | Animals | Alleles | Mice | Primary Cell Culture | Receptor, Notch1 - genetics | Receptors, Aryl Hydrocarbon - immunology | Intercellular Signaling Peptides and Proteins - immunology | Calcium-Binding Proteins - genetics | Receptors, Cell Surface - genetics | Medical colleges | Air pollution | Asthma | Antigens | Aqueous solutions | Cytokines | Dendritic cells | Lymphocytes | Atherosclerosis | Traffic | Atoms & subatomic particles | Hydrocarbons | Inflammation | Pollutants
Journal Article
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue 6, pp. 840 - 847
Journal Article
Journal of the American Heart Association, ISSN 2047-9980, 08/2013, Volume 2, Issue 4, pp. e000249 - n/a
Background Coronary artery disease leading to myocardial ischemia is the most common cause of heart failure. Apelin (APLN), the endogenous peptide ligand of... 
ischemia‐reperfusion injury | heart failure | cardiomyopathy | angiogenesis | myocardial infarction | CARDIAC-FUNCTION | CARDIAC & CARDIOVASCULAR SYSTEMS | HEART-FAILURE | IDENTIFICATION | ischemia-reperfusion injury | INHIBITION | RECEPTOR APJ | IN-VIVO | DISEASE | BLOOD-VESSELS | ENDOGENOUS INOTROPE APELIN | Myocardial Ischemia - genetics | Myocardial Ischemia - metabolism | Ventricular Function, Left | Myocardial Reperfusion Injury - mortality | Humans | Heart Failure - physiopathology | Male | Stem Cells - metabolism | Recovery of Function | Heart Failure - prevention & control | Myocardial Reperfusion Injury - pathology | Time Factors | Myocardium - metabolism | Myocardial Ischemia - mortality | Intercellular Signaling Peptides and Proteins - deficiency | Myocardial Reperfusion Injury - genetics | Apelin | Disease Models, Animal | Endothelial Cells - metabolism | Mice, Inbred C57BL | Intercellular Signaling Peptides and Proteins - genetics | Myocardial Ischemia - prevention & control | Myocardium - pathology | Heart Failure - metabolism | Adipokines | Ventricular Dysfunction, Left - physiopathology | Ventricular Dysfunction, Left - prevention & control | Cardiovascular Agents - pharmacology | Mice, Knockout | Myocardial Ischemia - pathology | Peptides - pharmacology | Ventricular Dysfunction, Left - metabolism | Myocardial Reperfusion Injury - metabolism | Animals | Intercellular Signaling Peptides and Proteins - pharmacology | Stem Cells - pathology | Mice | Endothelial Cells - pathology | Ventricular Remodeling - drug effects | Myocardial Reperfusion Injury - prevention & control | Neovascularization, Physiologic
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 10/2009, Volume 6, Issue 10, pp. 569 - 579
VEGFR inhibitors are in broad use for the treatment of metastatic renal-cell carcinoma, gastrointestinal stromal tumors and hepatocellular carcinoma and in... 
ADVANCED SOLID TUMORS | ONCOLOGY | ENDOTHELIAL-GROWTH-FACTOR | HIPPEL-LINDAU-DISEASE | TYROSINE KINASE INHIBITOR | VASCULAR-PERMEABILITY FACTOR | FOCAL ADHESION KINASE | ORALLY-ACTIVE INHIBITOR | ANTITUMOR-ACTIVITY | PHASE-I | I DOSE-ESCALATION | Niacinamide - analogs & derivatives | Cadherins - metabolism | United States | Humans | National Cancer Institute (U.S.) | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Structure-Activity Relationship | Integrins - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Clinical Trials, Phase III as Topic | Angiogenesis Inhibitors - therapeutic use | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Pyrroles - therapeutic use | Angiogenesis Inhibitors - adverse effects | Extracellular Matrix Proteins - metabolism | Peptide Hydrolases - metabolism | Pyridines - therapeutic use | Neoplasms - classification | Angiogenesis Inhibitors - pharmacokinetics | Neoplasms - drug therapy | Transcription Factors - metabolism | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Indoles - therapeutic use | Usage | Control | Physiological aspects | Genetic aspects | Angiogenesis inhibitors | Neovascularization | Research | Health aspects | Vascular endothelial growth factor
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 02/2018, Volume 20, Issue 2, pp. 319 - 327
Aims To investigate the chronic effects of twice‐daily administration of stable apelin analogues, apelin‐13 amide and pyroglutamyl (pGlu) apelin‐13 amide, on... 
apelin analogues | satiety | adipokine | diabetes | obesity | METABOLIC SYNDROME | AMIDE | INSULIN-SECRETION | GLP-1 RECEPTOR ACTIVATION | INDIVIDUALS | HYPERGLYCEMIA | LIFE-STYLE | EXENDIN-4 | GLUCOSE | PHARMACOLOGY | ENDOCRINOLOGY & METABOLISM | Obesity - drug therapy | Diet, High-Fat - adverse effects | Intercellular Signaling Peptides and Proteins - chemistry | Male | Diabetes Mellitus, Type 2 - metabolism | Weight Loss - drug effects | Exenatide - chemistry | Anti-Obesity Agents - therapeutic use | Glucagon-Like Peptide-1 Receptor - metabolism | Amides - adverse effects | Diabetes Mellitus, Type 2 - etiology | Obesity - etiology | Exenatide - adverse effects | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Exenatide - therapeutic use | Adiposity - drug effects | Drug Stability | Insulin Resistance | Obesity - physiopathology | Amides - therapeutic use | Energy Intake - drug effects | Hypoglycemic Agents - chemistry | Obesity - metabolism | Anti-Obesity Agents - chemistry | Animals | Amides - chemistry | Intercellular Signaling Peptides and Proteins - therapeutic use | Mice | Diabetes Mellitus, Type 2 - drug therapy | Energy Metabolism - drug effects | Glucagon-Like Peptide-1 Receptor - agonists | Intercellular Signaling Peptides and Proteins - adverse effects | Obesity | Diet therapy | Peptides | Blood sugar | Analysis | Low density lipoproteins | Body weight | Glycosylated hemoglobin | Insulin | Trans fatty acids | Lipoproteins (low density) | Glucagon | Body fat | Lipids | Glucose | Metabolic response | High fat diet | Rodents | Hemoglobin | Pancreas | Glucagon-like peptide 1 | Energy intake | Dual energy X-ray absorptiometry | Secretion | Diabetes mellitus | Energy expenditure | Triglycerides | Metabolism | Cholesterol | Feeding | Bone mineral content | Glucose tolerance | Food intake | Calorimetry | Chronic effects
Journal Article
Circulation, ISSN 0009-7322, 10/2003, Volume 108, Issue 16, pp. 1933 - 1938
Background -"Therapeutic angiogenesis" seeks to improve perfusion by the growth of new blood vessels. The Regional Angiogenesis with Vascular Endothelial... 
Peripheral vascular disease | Angiogenesis | Claudication | Viruses | Gene therapy | viruses | CILOSTAZOL | MULTICENTER | CARDIAC & CARDIOVASCULAR SYSTEMS | WALKING DISTANCES | VEGF121 CDNA | angiogenesis | gene therapy | ISCHEMIA | MEDIATED GENE-TRANSFER | peripheral vascular disease | VECTOR | TRIAL | THERAPY | NEOVASCULARIZATION | HEMATOLOGY | claudication | Neovascularization, Physiologic - drug effects | Vascular Endothelial Growth Factor A | Genetic Vectors - administration & dosage | Peripheral Vascular Diseases - therapy | Vascular Endothelial Growth Factors | Humans | Middle Aged | Male | Dose-Response Relationship, Drug | Endothelial Growth Factors - adverse effects | Lymphokines - adverse effects | Lymphokines - genetics | Adenoviridae - genetics | Female | Intermittent Claudication - therapy | Walking - statistics & numerical data | Intercellular Signaling Peptides and Proteins - administration & dosage | Double-Blind Method | Peripheral Vascular Diseases - complications | Intercellular Signaling Peptides and Proteins - genetics | Intermittent Claudication - etiology | Treatment Outcome | Lymphokines - administration & dosage | Endothelial Growth Factors - administration & dosage | Endothelial Growth Factors - genetics | Quality of Life | Aged | Edema - chemically induced | Intercellular Signaling Peptides and Proteins - adverse effects | Genetic Therapy - adverse effects | Genetic Therapy - methods
Journal Article
Brain, ISSN 0006-8950, 2012, Volume 135, Issue 6, pp. 1794 - 1818
Multiple sclerosis involves demyelination and axonal degeneration of the central nervous system. The molecular mechanisms of axonal degeneration are relatively... 
collapsin response mediator protein 2 | Nogo receptor | axonal degeneration | experimental autoimmune encephalomyelitis | Nogo-A | ENCEPHALOMYELITIS | FUNCTIONAL RECOVERY | RESPONSE MEDIATOR PROTEIN-2 | ALZHEIMERS-DISEASE | AXONAL REGENERATION | RHO-KINASE | NEUROSCIENCES | LESIONS | CLINICAL NEUROLOGY | MYELIN OLIGODENDROCYTE GLYCOPROTEIN | HYPERPHOSPHORYLATION | INHIBITOR | Humans | Middle Aged | Myelin Proteins - deficiency | Encephalomyelitis, Autoimmune, Experimental - immunology | tau Proteins - metabolism | Male | Green Fluorescent Proteins - genetics | Receptors, Cell Surface - antagonists & inhibitors | Nerve Degeneration - metabolism | Retinal Ganglion Cells - pathology | Time Factors | Nogo Receptor 1 | GPI-Linked Proteins - antagonists & inhibitors | Disease Models, Animal | Transduction, Genetic | Encephalomyelitis, Autoimmune, Experimental - drug therapy | Myelin Proteins - antagonists & inhibitors | Silver Staining | Myelin-Oligodendrocyte Glycoprotein | Glycoproteins - adverse effects | Mutation - genetics | CD3 Complex - metabolism | Receptors, Cell Surface - immunology | Mice, Knockout | Analysis of Variance | Axons - pathology | Encephalomyelitis, Autoimmune, Experimental - complications | Receptors, Cell Surface - deficiency | Cell Line, Tumor | Mice | Peptide Fragments - adverse effects | Nerve Degeneration - etiology | Neurofilament Proteins - metabolism | Optic Nerve - metabolism | Optic Nerve - pathology | Phosphorylation | Immunoprecipitation | Spinal Cord - metabolism | Demyelinating Diseases - metabolism | Retinal Ganglion Cells - metabolism | Intercellular Signaling Peptides and Proteins - metabolism | Tubulin - metabolism | GPI-Linked Proteins - deficiency | Spinal Cord - pathology | Axons - ultrastructure | Myelin Proteins - immunology | Adult | Female | Demyelinating Diseases - etiology | Demyelinating Diseases - pathology | Neuroblastoma - pathology | Severity of Illness Index | Antibodies - therapeutic use | Green Fluorescent Proteins - metabolism | GPI-Linked Proteins - immunology | Gene Expression Regulation - genetics | Mice, Inbred C57BL | Intercellular Signaling Peptides and Proteins - genetics | Axons - metabolism | Nerve Tissue Proteins - genetics | Multiple Sclerosis - complications | Nerve Tissue Proteins - metabolism | Animals | Multiple Sclerosis - pathology | Original
Journal Article